Zentalis Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
De winst van Zentalis Pharmaceuticals zal naar verwachting dalen met 0.1% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 37% per jaar. De winst per aandeel zal naar verwachting groeien met 8.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -107.1% zijn.
Belangrijke informatie
-0.1%
Groei van de winst
8.1%
Groei van de winst per aandeel
Biotechs winstgroei | 28.4% |
Inkomstengroei | 37.0% |
Toekomstig rendement op eigen vermogen | -107.1% |
Dekking van analisten | Good |
Laatst bijgewerkt | 15 Nov 2024 |
Recente toekomstige groei-updates
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Recent updates
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 23 | -246 | -220 | -268 | 8 |
12/31/2025 | N/A | -233 | -194 | -232 | 9 |
12/31/2024 | 41 | -173 | -169 | -174 | 11 |
9/30/2024 | 41 | -179 | -172 | -172 | N/A |
6/30/2024 | 41 | -195 | -167 | -166 | N/A |
3/31/2024 | 41 | -219 | -211 | -211 | N/A |
12/31/2023 | N/A | -292 | -208 | -208 | N/A |
9/30/2023 | N/A | -286 | -205 | -205 | N/A |
6/30/2023 | N/A | -285 | -201 | -199 | N/A |
3/31/2023 | N/A | -241 | -165 | -163 | N/A |
12/31/2022 | N/A | -237 | -166 | -164 | N/A |
9/30/2022 | N/A | -232 | -168 | -163 | N/A |
6/30/2022 | N/A | -182 | -169 | -164 | N/A |
3/31/2022 | N/A | -168 | -173 | -167 | N/A |
12/31/2021 | N/A | -159 | -160 | -154 | N/A |
9/30/2021 | N/A | -149 | -149 | -144 | N/A |
6/30/2021 | N/A | -179 | -133 | -132 | N/A |
3/31/2021 | N/A | -152 | -109 | -107 | N/A |
12/31/2020 | N/A | -118 | -88 | -87 | N/A |
9/30/2020 | N/A | -92 | -73 | -73 | N/A |
6/30/2020 | N/A | -70 | -62 | -62 | N/A |
3/31/2020 | N/A | -53 | -47 | -47 | N/A |
12/31/2019 | N/A | -46 | -39 | -39 | N/A |
12/31/2018 | 0 | -23 | -24 | -24 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ZNTL de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ZNTL de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ZNTL de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van ZNTL ( 37% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van ZNTL ( 37% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat ZNTL binnen 3 jaar verliesgevend zal zijn.